import type { DigestEntry } from './types';

// Cardiovascular Disease -- 9 entries, added 2026-08-08 as this app's
// seventeenth real condition, and its seventh genuinely non-autoimmune one
// (after PCOS, CKD, MASLD, Type 2 Diabetes, IBS, and Migraine). Named
// directly in CLAUDE.md's own Beyond Hashimoto's research, and already
// touched from five separate angles across this app's existing content
// before this category ever existed: lupus's own real 50-fold heart-attack
// risk in young women, Hashimoto's own organ-systems entry on hypothyroid
// heart effects, PCOS's own lipid-panel/cardiometabolic entry, and both
// psoriasis's and rheumatoid arthritis's own self-advocacy entries on
// elevated cardiovascular risk. This category is the first place any of
// those five threads gets its own dedicated, general cardiovascular-disease
// content to link back to.
//
// This session's own WebSearch budget was already exhausted before this
// category's research began (confirmed via a direct tool-system message),
// so every citation here was found via WebFetch against real, findable
// pages -- MedlinePlus (already proven reliable throughout this whole
// build) plus direct PubMed fetches against real PMIDs. Two real research
// limits: the PREDIMED trial's own
// exact reported hazard ratio could not be independently re-confirmed this
// session (the trial's own real, genuine 2018 retraction-and-republication
// is confirmed and cited, but the abstract's results section itself could
// not be successfully fetched, and two follow-up attempts at a direct
// primary source both failed), so this category's own PREDIMED entry
// describes the trial's real design and real retraction story honestly
// without stating an unverified specific number; and a dedicated apoB
// (apolipoprotein B) deep-dive was considered and deliberately folded into
// the lipid-panel self-advocacy entry as a brief, honestly-scoped mention
// rather than given its own entry, since a specific primary citation for it
// could not be independently confirmed this session either.
export const CARDIOVASCULAR_DISEASE_ENTRIES: DigestEntry[] = [
  {
    id: 'cvd-overview',
    category: 'cardiovascularDisease',
    title: "Cardiovascular Disease: A Category With Modifiable Risk Factors",
    teaser: "Heart disease remains the leading cause of death, and a substantial share of its risk factors are modifiable, including several that already show up elsewhere.",
    summary: "Cardiovascular disease covers a wide range of conditions affecting the heart and blood vessels, most seriously coronary artery disease, heart attack, and stroke, and it remains the leading cause of death. Standard medical guidance names a specific, modifiable set of risk factors: a diet high in saturated fat, refined carbohydrates, and salt, physical inactivity, excess alcohol use, smoking, and chronic stress. A specific, second category of risk factors matters directly for anyone: standard medical guidance explicitly names autoimmune and inflammatory diseases, chronic kidney disease, and metabolic syndrome among the medical conditions that raise cardiovascular risk, a direct, documented bridge to several conditions already built out here. Lupus carries a striking, independently documented risk (see the lupus research, covering a 50-fold increased heart attack risk in young women with lupus compared to their peers). Hashimoto's hypothyroidism has documented cardiovascular effects (see the organ-systems research). Rheumatoid arthritis and psoriasis both carry independently elevated cardiovascular risk of their own (see each condition's self-advocacy research). PCOS's insulin-resistance-driven lipid changes are a direct cardiometabolic link too (see the PCOS research). This category covers what's general to cardiovascular risk and its food-first management: diet patterns with trial evidence, medication evidence that's more mixed than commonly assumed, and self-advocacy around the lab tests and symptoms that matter most.",
    citations: [
      { source: 'Heart Disease, MedlinePlus, U.S. National Library of Medicine', url: 'https://medlineplus.gov/heartdiseases.html' },
    ],
    overallTier: 'strong',
    relatedIds: ['lupus-cardiovascular-risk', 'organ-cardiovascular', 'pcos-lipid-panel-cardiometabolic', 'psoriasis-advocacy-cardiovascular-metabolic', 'ra-advocacy-cardiovascular-risk', 'gout-urate-lowering-therapy', 'gout-metabolic-cluster-connection', 'vitamind-vital-trial-non-skeletal', 'prostate-vascular-ischemia-hypothesis', 'prostate-vascular-triad-luts-ed-cvd', 'bodyfat-hadza-cardiovascular-health'],
  },
  {
    id: 'cvd-mediterranean-diet-predimed',
    category: 'cardiovascularDisease',
    title: "The Mediterranean Diet: Trial Evidence, and a Retraction Story",
    teaser: "One of the most influential cardiovascular-prevention trials ever run was retracted and republished after a corrected error was found. The corrected version still supports the same conclusion.",
    summary:
      "PREDIMED (PREvención con DIeta MEDiterránea) is a large, landmark randomized controlled trial testing a Mediterranean diet, supplemented with either extra-virgin olive oil or mixed nuts, against a low-fat control diet for primary cardiovascular disease prevention in people at high cardiovascular risk but without diagnosed cardiovascular disease at the start. The original 2013 publication was formally retracted in 2018 after identified irregularities in how some study sites randomized participants, and the trial was re-analyzed and republished the same year in the same journal with corrected statistical methods. This is a documented correction to an influential trial, not a case where the underlying finding was overturned, the corrected, republished analysis reached the same substantive conclusion: a Mediterranean diet supplemented with olive oil or nuts reduced major cardiovascular events compared to the control diet. For anyone encountering an older reference to the original 2013 paper, the correct version to trust is the 2018 corrected republication, a useful example of how legitimate science self-corrects rather than a reason to distrust the underlying Mediterranean-diet evidence base, which remains substantial across many other independent studies too.",
    citations: [
      { source: 'Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts (corrected and republished), PMID 29897866', url: 'https://pubmed.ncbi.nlm.nih.gov/29897866/' },
    ],
    overallTier: 'strong',
    relatedIds: ['dietfat-saturated-monounsaturated-honest'],
  },
  {
    id: 'cvd-dash-sodium',
    category: 'cardiovascularDisease',
    title: "DASH and Sodium: A Specific Dietary Pattern Built Directly Around Blood Pressure",
    teaser: "DASH stands for Dietary Approaches to Stop Hypertension, and its sodium targets are specific enough to plan a day of eating around.",
    summary:
      "The DASH diet (Dietary Approaches to Stop Hypertension) is a specific eating pattern developed and studied directly for its effect on blood pressure, built around vegetables, fruits, whole grains, and low-fat dairy, with reduced saturated fat and reduced sodium. Current guidance from the National Heart, Lung, and Blood Institute sets a specific standard sodium target of under 2,300mg a day, with a lower, more effective target of 1,500mg a day named directly for anyone with existing high blood pressure or wanting a stronger effect. This is a food-first, specific-numbers approach rather than a vague \"eat less salt\" suggestion, and it's a direct, practical complement to the Mediterranean-diet evidence in this category's PREDIMED entry, both are whole-food, plant-forward patterns with independent cardiovascular trial support, rather than competing approaches.",
    citations: [
      { source: 'DASH Eating Plan, National Heart, Lung, and Blood Institute', url: 'https://www.nhlbi.nih.gov/education/dash-eating-plan' },
    ],
    overallTier: 'strong',
    relatedIds: ['magnesium-blood-pressure', 'potassium-sodium-balance'],
  },
  {
    id: 'cvd-statin-evidence',
    category: 'cardiovascularDisease',
    title: "Statins: A Large, Consistent Evidence Base Behind a Commonly Debated Medication",
    teaser: "Few medications attract as much online debate as statins. The pooled trial evidence behind them is unusually large and consistent.",
    summary:
      "Statins are among the most studied medications in cardiovascular medicine, and a major meta-analysis from the Cholesterol Treatment Trialists' Collaboration, pooling 14 randomized trials and 90,056 participants, found a specific, quantified benefit: each 1 mmol/L reduction in LDL cholesterol achieved with a statin tracked with a 12% reduction in all-cause mortality and a 21% reduction in major vascular events (heart attack, stroke, and the need for a revascularization procedure). This same large pooled analysis found no increase in cancer risk associated with statin use, directly addressing one of the most commonly repeated online concerns about this medication class. This is a large, consistent body of evidence, not a single small trial, and it's offered here as information to bring into a conversation with a prescriber, not as a substitute for one, since individual factors (existing liver disease, muscle-related side effects, personal risk level) affect whether a statin makes sense for any one person.",
    citations: [
      { source: 'Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins, PMID 16214597', url: 'https://pubmed.ncbi.nlm.nih.gov/16214597/' },
    ],
    overallTier: 'strong',
    relatedIds: ['foodhistory-cholesterol-real-drivers', 'masld-statin-safety-myth', 'ckd-sharp-trial-statins'],
  },
  {
    id: 'cvd-aspirin-primary-prevention-reversal',
    category: 'cardiovascularDisease',
    title: "Daily Aspirin for Prevention: A Documented Shift in Medical Guidance",
    teaser: "Daily low-dose aspirin was once widely recommended for cardiovascular prevention. A large trial helped change that guidance, for a quantified reason.",
    summary:
      "The large ASCEND trial (15,480 adults with diabetes but no diagnosed cardiovascular disease) tested daily low-dose aspirin specifically for primary prevention, meaning prevention in people who haven't yet had a cardiovascular event. Over a 7.4-year follow-up, aspirin reduced serious vascular events from 9.6% to 8.5% of participants, a benefit, but it also increased major bleeding events from 3.2% to 4.1% of participants. Converted into concrete numbers: aspirin prevented roughly 85 additional vascular events while causing roughly 90 additional major bleeding events per 10,000 people treated over that same period, the trial's authors wrote that \"the absolute benefits were largely counterbalanced by the bleeding hazard.\" This quantified, roughly even trade-off is the actual reason current guidance has shifted away from routinely recommending daily aspirin for primary prevention in people without existing cardiovascular disease, it's an individual risk-versus-benefit decision, not a settled yes-or-no answer, and it's a direct example of why a medication that helps one outcome can simultaneously carry a comparable cost in another.",
    citations: [
      { source: 'Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus (ASCEND), PMID 30146931', url: 'https://pubmed.ncbi.nlm.nih.gov/30146931/' },
    ],
    overallTier: 'strong',
    relatedIds: ['cvd-omega3-honest-null'],
  },
  {
    id: 'cvd-omega3-honest-null',
    category: 'cardiovascularDisease',
    title: "Omega-3 Supplements for Prevention: A Null Result From a Large Trial",
    teaser: "The same trial that reshaped aspirin guidance tested omega-3 supplements too, in the same population, at the same time, with a different result.",
    summary: "The same ASCEND trial covered in this category's aspirin entry also tested a daily 1g omega-3 fatty acid supplement, in the same 15,480 adults with diabetes and no diagnosed cardiovascular disease, over the same 7.4-year follow-up. The result here was null: 689 serious vascular events (8.9%) in the omega-3 group versus 712 (9.2%) in the placebo group, a rate ratio of 0.97 that did not reach statistical significance. A large, well-designed trial found no meaningful cardiovascular prevention benefit from omega-3 supplementation in this population, a different and more sobering result than the popular reputation omega-3 supplements often carry for heart health. Alongside separate evidence covered elsewhere connecting dietary omega-3 intake (not supplements specifically) to other outcomes: a supplement pill and a dietary pattern are not automatically interchangeable, and this trial's null result is specific to supplementation for this specific population and outcome, not a blanket statement about omega-3s overall.",
    citations: [
      { source: 'Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus (ASCEND), PMID 30146932', url: 'https://pubmed.ncbi.nlm.nih.gov/30146932/' },
    ],
    overallTier: 'strong',
    relatedIds: ['cvd-aspirin-primary-prevention-reversal', 'omega36-tying-together'],
    chart: {
      title: 'ASCEND Trial: Serious Vascular Events Over 7.4 Years',
      unit: '%',
      data: [
        { label: 'Omega-3 group', value: 8.9 },
        { label: 'Placebo group', value: 9.2 },
      ],
      sourceNote: 'ASCEND trial, PMID 30146932 (15,480 participants)',
    },
  },
  {
    id: 'cvd-lipid-panel-self-advocacy',
    category: 'cardiovascularDisease',
    title: "The Lipid Panel: Specific Testing Intervals, and a Note on What Standard Cholesterol Numbers Don't Capture",
    teaser: "How often a lipid panel actually needs repeating depends on specific factors like age and sex, not one blanket schedule for everyone.",
    summary: "Standard cholesterol-testing guidance sets specific intervals by age and risk: a first test between ages 9 and 11, then every 5 years through adulthood for most people, shifting to every 1 to 2 years for men 45 to 65 and women 55 to 65, and annual testing for adults over 65. For anyone with a condition that carries an elevated cardiovascular risk (lupus, rheumatoid arthritis, psoriasis, and PCOS all do, see this category's cross-links), a conversation with a prescriber about testing more often than the general schedule above is a reasonable, specific thing to raise. A separate concept for that same conversation: apolipoprotein B (apoB), a specific protein present on every atherogenic (artery-damaging) lipid particle, is a well-evidenced, more direct measure of cardiovascular risk than LDL cholesterol alone, since it counts particles rather than just their cholesterol content, see the dedicated Health Literacy entry on why that distinction actually matters, backed by a large, 52-country study. Worth raising directly by name in a conversation with a prescriber, especially for anyone whose standard LDL number looks normal but who still carries other risk factors.",
    citations: [
      { source: 'Cholesterol Levels: What You Need to Know, MedlinePlus, U.S. National Library of Medicine', url: 'https://medlineplus.gov/cholesterollevelswhatyouneedtoknow.html' },
    ],
    overallTier: 'strong',
    relatedIds: ['pcos-lipid-panel-cardiometabolic', 'foodhistory-apob-particle-count'],
  },
  {
    id: 'cvd-heart-attack-red-flags',
    category: 'cardiovascularDisease',
    title: "Heart Attack Red Flags: Specific Symptoms, Including a Documented Pattern That Differs by Sex",
    teaser: "Chest pain is the symptom most people expect. Documented evidence shows women often experience a different, easier-to-miss pattern.",
    summary:
      "Standard emergency guidance names a specific set of heart attack warning symptoms: chest discomfort (pressure, squeezing, or pain), shortness of breath, discomfort spreading to the upper body (arms, back, neck, jaw, or stomach), and a cluster of accompanying symptoms including nausea, vomiting, dizziness, or a cold sweat. A specific, documented pattern: women are more likely than men to experience atypical symptoms during a heart attack, most notably unusual fatigue, rather than the classic crushing chest pain pattern more commonly described in men, a documented reason heart attacks in women are more often missed or delayed in diagnosis. Any of these symptoms, especially in combination, warrant immediate emergency evaluation, not a wait-and-see approach, since treatment for a heart attack is significantly more effective the sooner it starts.",
    citations: [
      { source: 'Heart Attack, MedlinePlus, U.S. National Library of Medicine', url: 'https://medlineplus.gov/heartattack.html' },
    ],
    overallTier: 'strong',
  },
  {
    id: 'cvd-tying-together',
    category: 'cardiovascularDisease',
    title: "What Actually Holds Up for Cardiovascular Disease, Pulled Together",
    teaser: "A whole-food dietary pattern with trial support, a commonly debated medication class with unusually strong evidence behind it, and two examples of guidance changing because a large trial said so.",
    summary: "Line up everything in this category and cardiovascular disease reads as a condition where whole-food dietary patterns (the Mediterranean diet, DASH) carry strong, trial-backed evidence, where statins carry a large, consistent evidence base despite their commonly debated reputation, and where two of the most significant recent shifts in cardiovascular guidance, daily aspirin for primary prevention and omega-3 supplementation, both came from the same large trial finding that the numbers simply didn't support the older, more routine recommendation. Medical guidance changing because trial evidence said so is the system working, not a reason for distrust. And for anyone managing one of the several other conditions that carry their documented, elevated cardiovascular risk (lupus, rheumatoid arthritis, psoriasis, PCOS, and Hashimoto's hypothyroid effects all do), this category's specific self-advocacy content, on lipid testing intervals and on recognizing an emergency immediately, is worth treating as directly relevant, not background reading.",
    citations: [
      { source: 'Heart Disease, MedlinePlus, U.S. National Library of Medicine', url: 'https://medlineplus.gov/heartdiseases.html' },
    ],
    overallTier: 'strong',
    relatedIds: ['cvd-mediterranean-diet-predimed', 'cvd-statin-evidence', 'cvd-aspirin-primary-prevention-reversal', 'cvd-omega3-honest-null', 'cvd-lipid-panel-self-advocacy'],
  },

  // -- Full-depth parity additions, 2026-08-08. Every citation
  // independently verified via WebSearch.
  {
    id: 'cvd-heart-failure-abcd-staging',
    category: 'cardiovascularDisease',
    title: "Heart Failure Has a Formal 4-Stage System, and Stage A Applies to Common Risk Factors Before Any Heart Damage Has Actually Happened",
    teaser: 'Stage A means no heart damage yet, just risk factors like hypertension or diabetes already present, the formal system moves one direction only, and never back.',
    summary: "Heart failure runs on a formal ACC/AHA 4-stage classification, different from how most people think of \"stages\" of illness: Stage A (\"at risk\") applies to someone with common risk factors, hypertension, diabetes, metabolic syndrome, or a family history of cardiomyopathy, but with NO actual heart damage yet, meaning a large share of the audience already sits somewhere in this staging system without a heart failure diagnosis at all. Stage B (\"pre-heart failure\") means structural heart changes or elevated cardiac biomarkers are present, but still no actual symptoms. Stage C is symptomatic heart failure, current or past. Stage D is advanced, refractory heart failure requiring specialized intervention. The important structural fact: this staging system moves in only one direction, someone can progress from Stage A to B to C, but current guidance treats these stages as NOT reversible backward, distinct from the NYHA functional class (a separate measure of current symptom severity) which can improve with treatment even as the underlying ACC/AHA stage itself doesn't move back.",
    citations: [
      { source: '2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure, Circulation', url: 'https://www.ahajournals.org/doi/10.1161/CIR.0000000000001063' },
    ],
    overallTier: 'strong',
  },
  {
    id: 'cvd-kidney-brain-pad-real-data',
    category: 'cardiovascularDisease',
    title: "CVD's Reach Into the Kidneys, Brain, and Legs, One Shared Disease Process Showing Up in Three Different Places",
    teaser: 'Research finds peripheral artery disease affecting over 200 million people worldwide, and a direct link between vascular disease and dementia risk, all one shared atherosclerotic process, not three separate diseases.',
    summary: "Cardiovascular disease's underlying process, atherosclerosis, doesn't confine itself to the heart. Peripheral artery disease (PAD), obstructive atherosclerosis reaching the legs specifically, affects an estimated 200+ million people worldwide, and research treats it as a direct marker of the SAME systemic process already elevating heart attack and stroke risk, not a separate, unrelated leg problem. Documented brain effects are just as direct: vascular disease in the brain's arteries is an established contributor to vascular dementia, and research finds atherosclerotic vascular disease independently linked to cognitive impairment, particularly when it shows up as POLYVASCULAR disease (affecting multiple vessel territories at once) or occurs alongside chronic kidney disease specifically, covered in the CKD research. This three-way overlap (heart, brain, kidney) is a direct reason CVD risk factors matter well beyond the heart alone, the same shared vascular process simply showing up wherever a person's particular vulnerability happens to be greatest.",
    citations: [
      { source: 'Cardiovascular Prognosis in Patients with Peripheral Artery Disease and Approach to Therapy, PMC10740501', url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10740501/' },
    ],
    overallTier: 'strong',
    relatedIds: ['ckd-mineral-bone-cardiovascular-real-data', 'cvd-myocardial-ischemia-neurogenesis-impairment'],
  },
  {
    id: 'cvd-history-milestones',
    category: 'cardiovascularDisease',
    title: "CVD's History: A Single, Ongoing Town Study That Built Modern Cardiology's Whole Risk-Factor Framework",
    teaser: '1948, 1987, one still-running study named the risk factors the research is built on, and a fungal extract became the drug that transformed treating them.',
    summary: "CVD's modern understanding traces to a single, remarkably influential project: the Framingham Heart Study, launched in 1948 to follow a large group of initially healthy people over time and identify what actually drove cardiovascular disease, at a moment when basic causes were still largely unknown despite CVD deaths having climbed steadily for decades. Seminal findings from this same still-running study first established smoking and high cholesterol as documented cardiovascular risk factors, the actual scientific foundation the lipid-panel and statin research builds on. The transformative treatment breakthrough came decades later: Japanese scientist Akira Endo discovered the first statin compound (compactin) from a fungal extract in 1976, and on September 1, 1987, lovastatin became the first statin approved by the FDA, a revolution in treating high cholesterol that reached over $1 billion in annual sales, with several more statins (simvastatin, pravastatin, atorvastatin, rosuvastatin, all still in use today) following through the 1990s and early 2000s.",
    citations: [
      { source: 'History, Framingham Heart Study', url: 'https://www.framinghamheartstudy.org/fhs-about/history/' },
    ],
    overallTier: 'strong',
    relatedIds: ['cvd-statin-evidence'],
  },
  {
    id: 'cvd-pregnancy-mwho-ppcm',
    category: 'cardiovascularDisease',
    title: "Heart Disease and Pregnancy: A Formal Risk-Classification System, and a Pregnancy-Specific Heart Failure That Can Strike Someone With No Prior Heart Disease at All",
    teaser: "The mWHO classification runs from no-added-risk conditions to conditions where pregnancy itself may not be advisable, and peripartum cardiomyopathy is a different risk that doesn't require any pre-existing heart condition to begin with.",
    summary:
      "Pre-existing heart disease and pregnancy carry a formal risk-stratification system, the modified WHO (mWHO) classification, running from Class I (no detectable added maternal risk) through Class II (small added risk) and Class III (significant risk requiring expert counseling and intensive monitoring) to Class IV (extremely high risk, where pregnancy itself may not be medically advisable). A second tool, CARPREG II, adds further precision, factoring in functional class, prior cardiac events, and specific findings like a mechanical heart valve or reduced ejection fraction. The distinct risk: peripartum cardiomyopathy (PPCM), heart failure that develops specifically in the last month of pregnancy through 5 months postpartum, striking people with NO prior heart disease at all, affecting an estimated 1 in 1,000 to 1 in 4,000 pregnancies. Encouraging recovery data exists too: a measured ejection fraction of 52% or higher, or a specific strain measurement below a threshold, is associated with low risk of PPCM recurring in a future pregnancy, a relevant reassurance for anyone who has recovered from a first episode and is considering another pregnancy.",
    citations: [
      { source: 'Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy, PMID 33609068', url: 'https://pubmed.ncbi.nlm.nih.gov/33609068/' },
    ],
    overallTier: 'strong',
  },

  // -- Second depth pass, 2026-08-08, continuing the full-parity work
  // beyond the first structural pass. Every citation independently
  // verified via WebSearch.
  {
    id: 'cvd-cantos-inflammation-hypothesis',
    category: 'cardiovascularDisease',
    title: 'A Landmark Trial Proved Cardiovascular Risk Can Be Lowered by Fighting Inflammation Alone, With No Cholesterol Change at All',
    teaser: 'The CANTOS trial gave a pure anti-inflammatory drug to 10,061 heart attack survivors and found significant risk reduction, with zero effect on cholesterol, directly separating inflammation from lipids as two independent levers.',
    summary: "The CANTOS trial (10,061 people who had already survived a heart attack, all with elevated hs-CRP, the same inflammatory marker covered in the self-advocacy research) tested canakinumab, a drug that blocks a specific inflammatory signaling molecule (IL-1beta) and does essentially nothing to cholesterol. Results at the effective dose found a significant reduction in major cardiovascular events (hazard ratio 0.85 versus placebo), while hs-CRP and IL-6 both dropped significantly and LDL cholesterol did NOT change at all. This is the first phase 3 trial evidence that inflammation itself, independent of cholesterol, is a directly treatable driver of cardiovascular risk, not just a marker that happens to travel alongside it. The limits: the effect size was modest, there was no significant reduction in overall mortality, and the drug carried an increased risk of fatal infection, reasons this specific drug hasn't become standard practice despite the finding's scientific significance. The lasting takeaway isn't the drug itself, it's the concept it proved: inflammation and cholesterol are two separate, independently treatable pathways to cardiovascular risk, not one and the same thing.",
    citations: [
      { source: 'Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease, New England Journal of Medicine', url: 'https://www.nejm.org/doi/full/10.1056/NEJMoa1707914' },
    ],
    overallTier: 'strong',
    relatedIds: ['cvd-lipid-panel-self-advocacy'],
  },

  // -- Volumetric depth pass, 2026-08-08, continuing full-parity work
  // beyond the second structural depth pass, working toward Hashimoto's
  // own real 176-entry depth. Every citation independently verified via
  // WebSearch.
  {
    id: 'cvd-lipoprotein-a-underrecognized',
    category: 'cardiovascularDisease',
    title: 'Lipoprotein(a) Is a Common, Almost Entirely Genetic Cardiovascular Risk Most People Have Never Been Tested For',
    teaser: 'A largely inherited cholesterol-like particle affects roughly 1 in 5 people worldwide, carries an independent stroke and heart-disease risk, and current guidelines recommend testing for it just once in a lifetime.',
    summary: "Lipoprotein(a), usually written Lp(a), is a genetically determined, cholesterol-carrying particle that behaves differently from the LDL and HDL covered in the lipid-panel self-advocacy research, and it's underrecognized in routine care. Research finds elevated Lp(a) affects an estimated 20% of the global population, roughly 1.4 billion people, and high-quality epidemiological and genetic evidence supports an independent, causal role in coronary artery disease, peripheral artery disease, ischemic stroke, calcific aortic valve disease, and atrial fibrillation, on top of whatever a person's LDL or total cholesterol already shows. Unlike LDL, Lp(a) levels are set almost entirely by genetics and stay stable throughout adult life, meaning current European Society of Cardiology guidance recommends testing for it just once, ever, not repeatedly like a standard lipid panel. A normal LDL result does not rule out an elevated Lp(a)-driven risk, and knowing an elevated Lp(a) can meaningfully reclassify someone's overall cardiovascular risk and justify more intensive management of the OTHER, modifiable risk factors covered in the cardiovascular research, since Lp(a) itself isn't something diet or exercise can substantially move.",
    citations: [
      { source: 'Lipoprotein(a) is a Prevalent yet Vastly Underrecognized Risk Factor for Cardiovascular Disease, PMC10959503', url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10959503/' },
      { source: 'Lipoprotein(a): the underutilized risk factor for cardiovascular disease, PMC6865184', url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6865184/' },
    ],
    overallTier: 'strong',
    relatedIds: ['cvd-lipid-panel-self-advocacy'],
  },
  {
    id: 'cvd-cardiac-rehabilitation-underused',
    category: 'cardiovascularDisease',
    title: 'Cardiac Rehabilitation Cuts Mortality by Roughly a Quarter, Yet Fewer Than 1 in 3 Eligible People Ever Enroll',
    teaser: 'A structured, supervised exercise-and-education program after a heart event lowers cardiovascular mortality by around 26-31% in meta-analyses, but global enrollment sits under 30%.',
    summary: "Cardiac rehabilitation, a structured program combining supervised exercise, education, and risk-factor counseling after a heart attack, heart surgery, or a heart failure diagnosis, carries some of the strongest mortality-reduction evidence of any intervention covered in the cardiovascular research, and it's underused. Meta-analyses find a 26% reduction in cardiovascular mortality at longest follow-up, with one analysis specifically finding a 27% reduction in all-cause mortality and 31% reduction in cardiac deaths among participants. The benefit is dose-dependent too, more sessions attended tracks with lower mortality, with research suggesting a minimum of around 36 sessions may be needed for the strongest measurable benefit. Despite this well-established evidence, global enrollment in cardiac rehabilitation programs remains under 30% of people who would actually qualify for one. Anyone who has had a heart attack, stent, bypass surgery, or a heart failure diagnosis has a concrete reason to ask specifically about a referral to cardiac rehabilitation, not just general exercise advice, since the structured, supervised program itself is what the mortality data is actually measuring.",
    citations: [
      { source: 'Exercise-based cardiac rehabilitation for coronary heart disease: a meta-analysis, European Heart Journal (Oxford Academic)', url: 'https://academic.oup.com/eurheartj/article/44/6/452/7028725' },
      { source: 'The Effectiveness of Cardiac Rehabilitation Programs in Improving Cardiovascular Outcomes: Systematic Review and Meta-Analysis, PMC11588675', url: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11588675/' },
    ],
    overallTier: 'strong',
    relatedIds: ['cvd-overview'],
  },
  {
    id: 'cvd-holiday-heart-alcohol-afib',
    category: 'cardiovascularDisease',
    title: '"Holiday Heart Syndrome": A Named Pattern of Binge Drinking Triggering Atrial Fibrillation in Otherwise Healthy Hearts',
    teaser: 'Research finds binge drinking can trigger atrial fibrillation even in people with no underlying heart disease, most often 12-36 hours after the drinking episode ends, in a well-documented, named clinical pattern.',
    summary: "Holiday heart syndrome is a formally named clinical pattern, first described after doctors noticed a cluster of otherwise healthy patients developing atrial fibrillation (AFib) after weekend binge-drinking episodes, and it remains common in emergency rooms today. Research finds alcohol serving as the precipitating factor in 35% to 62% of AFib cases seen this way, typically appearing 12 to 36 hours after binge drinking stops, notably during the withdrawal period rather than while actively intoxicated. The proposed mechanisms include acute alcohol raising sympathetic nervous system activity while reducing vagal tone, and alcohol increasing activity of specific calcium channels tied to atrial electrical instability. Important to know directly: this can happen even in people who rarely or never drink otherwise, and even in hearts with no pre-existing disease, meaning a single binge-drinking episode carries an immediate arrhythmia risk independent of someone's long-term drinking pattern. This connects directly to the alcohol advisory research, adding an acute, rhythm-specific risk to the more familiar long-term cardiovascular concerns already discussed there.",
    citations: [
      { source: 'Holiday Heart Syndrome: A Literature Review, PMC11955153', url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955153/' },
      { source: 'Holiday Heart Syndrome, StatPearls / NCBI Bookshelf', url: 'https://www.ncbi.nlm.nih.gov/books/NBK537185/' },
    ],
    overallTier: 'strong',
    relatedIds: ['cvd-overview'],
  },

  // -- Volumetric depth pass batch 3, 2026-08-08, continuing toward
  // genuine volumetric parity with Hashimoto's own depth. Every citation
  // independently verified via WebSearch.
  {
    id: 'cvd-triglycerides-omega3-real-data',
    category: 'cardiovascularDisease',
    title: 'Triglycerides Are a Distinct Cardiovascular Risk Marker, and Omega-3 Lowers Them, Though the Full Benefit May Run Deeper',
    teaser: 'A purified EPA formulation cut major cardiovascular events by 25% in a landmark trial, a benefit research finds too large to be explained by its triglyceride-lowering effect alone.',
    summary: "Triglycerides are a distinct blood fat marker from the LDL cholesterol covered in the lipid-panel research, and elevated triglycerides carry their independent cardiovascular risk. Research finds omega-3 fatty acids substantially lower triglycerides, a daily intake of 3-4g combined EPA+DHA reducing triglyceride levels by 20-50% in people with elevated baseline levels, with one trial finding a 27% reduction at the higher dose tested. The landmark REDUCE-IT trial tested a purified, high-dose EPA formulation (icosapent ethyl) specifically and found a striking 25% reduction in major cardiovascular events, distinguishing it directly from the null omega-3 supplement findings covered elsewhere in the CVD research (which typically tested lower-dose, mixed EPA/DHA formulations). Research finds the size of this cardiovascular benefit disproportionately large compared to the triglyceride reduction alone, suggesting omega-3, at least in this specific purified, high-dose form, may work through additional mechanisms, reduced blood pressure, an antithrombotic (clot-preventing) effect, improved inflammatory status, and better endothelial (blood vessel lining) function. This is a meaningful complication to the existing omega-3-and-heart-disease conversation, dose and formulation matter, and someone with elevated triglycerides specifically has a different evidence picture to discuss with a doctor than the general omega-3 supplement question.",
    citations: [
      { source: 'Rounding the corner on residual risk: Implications of REDUCE-IT for omega-3 polyunsaturated fatty acids treatment in secondary prevention of atherosclerotic cardiovascular disease, PMC6727875', url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6727875/' },
      { source: 'Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function, PMC3138218', url: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC3138218/' },
    ],
    overallTier: 'strong',
    relatedIds: ['cvd-omega3-honest-null', 'cvd-lipid-panel-self-advocacy'],
  },
  {
    id: 'cvd-resistant-hypertension-adherence',
    category: 'cardiovascularDisease',
    title: 'Medication Nonadherence Is Hiding Underneath a Striking Share of "Resistant" High Blood Pressure Cases',
    teaser: 'Repeated blood-tests-for-drug-levels research finds up to a third of people believed to be taking their blood pressure medication faithfully actually weren\'t, a complication before assuming a treatment itself has failed.',
    summary:
      "Resistant hypertension, blood pressure that stays elevated despite three or more medications, affects a substantial 4.3-29.7% of treated hypertension patients depending on the population studied. Research finds medication nonadherence hiding underneath a striking share of these cases, one study found repeated measurements of actual drug levels in the blood revealed nonadherence in a full third of patients who had previously been judged adherent through less rigorous monitoring (directly observed therapy). Real-world data finds this pattern consistently: one study found only 42% overall adherence among newly treated hypertensive patients, another found 45% of resistant hypertension patients showing poor adherence at baseline, and among patients using three or more blood pressure medications, research found only 34% adherent and just 13.7% actually reaching their blood pressure target. Reassuringly, research finds patients who ARE adherent show meaningfully greater blood pressure reductions than nonadherent patients, meaning the medications themselves generally do work when actually taken as prescribed. Before assuming truly resistant, treatment-refractory hypertension, it's worth examining practical barriers to taking medication consistently (cost, side effects, complicated dosing schedules, simply forgetting), since research finds this explains a meaningful share of what initially looks like resistant disease, and addressing it directly can be more effective than adding yet another medication.",
    citations: [
      { source: 'Nonadherence by Serum Drug Analyses in Resistant Hypertension: 7-Year Follow-Up of Patients Considered Adherent by Directly Observed Therapy, PMC9683683', url: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC9683683/' },
      { source: 'Medication Adherence and Treatment-Resistant Hypertension in Newly Treated Hypertensive Patients in the UAE, PMC8584664', url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584664/' },
    ],
    overallTier: 'strong',
    relatedIds: ['cvd-dash-sodium'],
  },
  {
    id: 'cvd-women-underdiagnosis-gender-gap',
    category: 'cardiovascularDisease',
    title: 'Women Are Systematically More Likely to Have Their Heart Disease Missed, Dismissed, or Undertreated',
    teaser: 'Research found women under 55 seven times more likely than men to be sent home from the ER without proper cardiac testing, with women\'s different symptom pattern a part of why.',
    summary: "Women face a well-documented gender gap in how heart disease is recognized and treated, not a fully solved problem. Research published in the Journal of the American Heart Association found women under 55 were seven times more likely than men to be sent home from the emergency room without proper cardiac testing. Research finds women also less likely to receive diagnostic imaging, artery-opening procedures (percutaneous coronary intervention), and statin therapy, even when presenting with clinically comparable symptoms to men. A part of the explanation: women's heart attack symptoms often differ from the classic crushing-chest-pain picture most diagnostic training is built around, research finds women more likely to experience generalized discomfort alongside nausea, fatigue, back pain, palpitations, and shortness of breath, sometimes as intermittent symptoms lasting hours, days, or even weeks before a full event. Research finds these less \"classic\" presentations directly contribute to delayed or compromised diagnosis, and that women's symptoms are more likely to be dismissed or minimized, particularly when described in vague or emotionally-expressed terms. This context matters by name for any woman experiencing unusual, hard-to-pin-down symptoms alongside cardiovascular risk factors, self-advocacy (covered elsewhere in the research) matters here specifically because the standard diagnostic pattern wasn't built around women's more varied presentation.",
    citations: [
      { source: 'Gender Disparities in Ischemic Heart Disease Management: Underdiagnosis in Women and Differences in Treatment, PMC12425171', url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12425171/' },
      { source: 'Women Acute Myocardial Infarction—Identifying and Understanding the Gender Gap (WAMy-GAP): A Study Protocol, PMC11121322', url: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11121322/' },
    ],
    overallTier: 'strong',
    relatedIds: ['cvd-heart-attack-red-flags', 'pcos-long-term-cardiovascular-risk'],
  },
  {
    id: 'cvd-coronary-calcium-score',
    category: 'cardiovascularDisease',
    title: 'A Coronary Calcium Score of Zero Is Useful Information, but It Has an Expiration Date',
    teaser: 'A coronary calcium scan can spot plaque before any symptom shows up, and a score of zero lowers risk, but a large MESA analysis found it isn\'t a lifetime guarantee.',
    summary:
      "A coronary artery calcium (CAC) scan is a low-radiation CT scan that directly counts calcium deposits in the heart's arteries, a physical measure of plaque rather than an estimate built from risk-factor questionnaires alone. Large cohort studies, most notably the Multi-Ethnic Study of Atherosclerosis (MESA), have repeatedly found CAC adds independent predictive value on top of standard risk calculators like the pooled cohort equations, and a score of zero is useful: it identifies people at very low near-term risk and can reasonably de-escalate a decision about starting a statin. A MESA analysis following 3,116 people with a baseline score of zero found that score doesn't hold indefinitely. About 19% of the 10-year coronary events in that whole cohort happened to people who still scored zero the last time they were checked, and once a repeat scan found any new calcium at all, it came before 55% of the future events and marked a roughly three-fold higher risk group. The estimated 'warranty period' for a zero score ran 3 to 7 years depending on sex, race and ethnicity, and was shorter specifically for anyone with diabetes. For someone whose family history or other risk factors leave uncertainty about their cardiovascular risk, a CAC scan is a concrete test to ask about, and a favorable score today is reassuring without being a permanent answer.",
    citations: [
      { source: "Warranty Period of a Calcium Score of Zero: Comprehensive Analysis From MESA, JACC: Cardiovascular Imaging 2021, PMID 33129734", url: 'https://pubmed.ncbi.nlm.nih.gov/33129734/' },
    ],
    overallTier: 'strong',
    relatedIds: ['cvd-lipid-panel-self-advocacy', 'cvd-lipoprotein-a-underrecognized'],
  },
  {
    id: 'cvd-atrial-fibrillation-anticoagulation',
    category: 'cardiovascularDisease',
    title: 'Atrial Fibrillation Raises Stroke Risk Fivefold, and a Well-Studied Treatment Cuts Most of It Back',
    teaser: 'A large pooled analysis of 29 trials found blood thinners cut stroke risk in atrial fibrillation by roughly 60%, one of the more decisive treatment effects in all of cardiovascular medicine.',
    summary:
      "Atrial fibrillation (AFib), an irregular, often rapid heart rhythm originating in the heart's upper chambers, raises stroke risk on its own, since blood can pool and clot inside a heart that isn't beating in its normal, coordinated rhythm. A large meta-analysis pooling 29 randomized trials and over 28,000 participants found adjusted-dose warfarin reduced stroke by roughly 60% compared with no treatment, one of the largest, most consistent treatment effects found anywhere in cardiovascular medicine, with newer direct oral anticoagulants (the 'NOAC' or 'DOAC' class) showing comparably strong protection in later trials and generally easier day-to-day management than warfarin's diet-and-monitoring requirements. Current clinical practice uses a specific, points-based tool, CHA2DS2-VASc, to decide who needs this protection, counting age, sex, and a specific list of medical conditions (heart failure, high blood pressure, diabetes, prior stroke or clot, vascular disease) toward an actual treatment threshold rather than a vague 'high risk' judgment call. Real-world data has repeatedly found a gap between this clear guidance and actual practice, with a meaningful share of people who score high enough to clearly benefit from anticoagulation not receiving it, often out of an understandable but not always well-calibrated worry about bleeding risk. Anyone diagnosed with AFib has concrete standing to ask directly where their CHA2DS2-VASc score lands and what it means for their treatment plan.",
    citations: [
      { source: 'Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation, Annals of Internal Medicine 2007 (Hart, Pearce, Aguilar), PMID 17577005', url: 'https://pubmed.ncbi.nlm.nih.gov/17577005/' },
    ],
    overallTier: 'strong',
    relatedIds: ['cvd-holiday-heart-alcohol-afib', 'cvd-heart-failure-abcd-staging'],
  },
  {
    id: 'cvd-polypill-primary-prevention',
    category: 'cardiovascularDisease',
    title: 'A Single Combination Pill Cut Major Cardiovascular Events by a Substantial Margin in Two Large Trials',
    teaser: 'A 5-year trial of over 50,000 people found a fixed-dose combination pill (blood pressure medication, a statin, and aspirin) reduced major cardiovascular events by a 34% versus standard lifestyle advice alone.',
    summary: "The 'polypill' idea is simple: combine several already-proven, low-cost cardiovascular medications (a blood-pressure drug, a statin, and often low-dose aspirin) into one single daily pill, specifically to make consistent, real-world adherence easier than juggling several separate prescriptions. Large trials have now tested this directly. The PolyIran trial, a pragmatic cluster-randomized study nested within a cohort of over 50,000 people, found a four-component polypill (aspirin, atorvastatin, hydrochlorothiazide, and either enalapril or valsartan) reduced major cardiovascular events by a 34% over 5 years compared with lifestyle advice alone (5.9% versus 8.8% of participants affected), with no increase in bleeding-related adverse events. A separate trial (TIPS-3) found adding aspirin to a similar polypill combination reduced its composite cardiovascular endpoint by a 31%. This is large-scale evidence that the SIMPLICITY of taking one pill, not just which specific medications it contains, appears to improve outcomes, most plausibly by improving how consistently people actually take their medication day to day. The evidence for each individual component (statins, DASH-style blood pressure management, low-dose aspirin's tradeoffs) still applies, the polypill strategy is a practical delivery method, not a different set of medications.",
    citations: [
      { source: 'Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial, The Lancet 2019, PMID 31448738', url: 'https://pubmed.ncbi.nlm.nih.gov/31448738/' },
    ],
    overallTier: 'strong',
    relatedIds: ['cvd-statin-evidence', 'cvd-dash-sodium', 'cvd-aspirin-primary-prevention-reversal'],
  },
  {
    id: 'cvd-air-pollution-pm25-real-data',
    category: 'cardiovascularDisease',
    title: 'Fine Particle Air Pollution Carries a Quantified, Independent Heart Attack Risk',
    teaser: 'A meta-analysis found short-term spikes in PM2.5 air pollution measurably raised heart attack risk within days, and long-term exposure carried a substantially larger cumulative effect.',
    summary:
      "Fine particulate air pollution (PM2.5, particles small enough to be inhaled deep into the lungs and cross into the bloodstream) carries independently documented cardiovascular risk, distinct from and additive to the diet, medication, and lifestyle factors. A meta-analysis of 34 studies found each 10 microgram-per-cubic-meter rise in short-term PM2.5 exposure tracked with a measurable 2.5% increase in heart attack risk within days, and a separate meta-analysis found long-term exposure carried a substantially larger cumulative effect, a 18% increase in heart attack risk per the same 10 microgram increment sustained over time. The proposed mechanisms include direct vascular inflammation, oxidative stress, and effects on the autonomic nervous system's regulation of heart rhythm and blood pressure. Any single day's individual relative risk increase is modest, but research finds that because hundreds of millions of people are continuously exposed, short-term PM2.5 spikes alone account for up to 5% of all heart attacks worldwide, a population-level burden from a widely shared, mostly involuntary exposure. Practical steps (checking a local air-quality index on high-pollution days, an indoor air filter, reducing outdoor exertion during spikes) are a concrete, if modest, addition to the cardiovascular risk-reduction levers.",
    citations: [
      { source: 'Association between PM2.5 and risk of hospitalization for myocardial infarction: a systematic review and a meta-analysis, BMC Public Health 2020, PMID 32164596', url: 'https://pubmed.ncbi.nlm.nih.gov/32164596/' },
    ],
    overallTier: 'strong',
    relatedIds: ['cvd-resistant-hypertension-adherence'],
  },
  {
    id: 'cvd-elderly-atypical-mi-presentation',
    category: 'cardiovascularDisease',
    title: 'Heart Attacks in Older Adults Often Skip Chest Pain Entirely, a Documented Age Effect',
    teaser: 'Silent or atypical heart attacks make up more than 60% of cases in adults over 60, presenting as confusion, weakness, or falling rather than classic chest pain.',
    summary:
      "The 'classic' heart attack picture, crushing chest pain radiating down the arm, is less reliable with age. Silent myocardial infarctions (heart attacks with no recognized symptoms at the time) make up as much as 54% of all heart attacks in the general population and more than 60% in adults over 60, and the reasons compound with age: autonomic nerve changes, cumulative damage to the heart's sensory nerves from prior ischemia, a higher pain threshold, and overlapping cognitive or neurological conditions all blunt the classic warning signal. When an older adult does have a recognized heart attack, dyspnea (shortness of breath) is frequently the dominant symptom rather than chest pressure, and geriatric medicine has a specific pattern: new confusion, unusual weakness, loss of appetite, or an unexplained fall can all be the presenting sign of a heart attack in an older person, standing in for the chest pain a younger patient would report. Autopsy data shows how easily this gets missed: in one large elderly series, the correct heart attack diagnosis had been made in life in fewer than half of cases, especially among the oldest patients. For anyone caring for or checking in on an older adult, a sudden change in mental clarity, energy, or balance deserves the same urgency a chest-pain complaint would get, not a slower, wait-and-see response.",
    citations: [
      { source: 'Atypical manifestation of myocardial ischemia in the elderly, Clinics in Geriatric Medicine, PMID 24714791', url: 'https://pubmed.ncbi.nlm.nih.gov/24714791/' },
    ],
    overallTier: 'strong',
    relatedIds: ['cvd-heart-attack-red-flags', 'cvd-women-underdiagnosis-gender-gap'],
  },
  {
    id: 'cvd-global-seven-countries-mediterranean',
    category: 'cardiovascularDisease',
    title: 'The Seven Countries Study Found Southern Europe at 2-10% Heart Disease Prevalence, Northern Europe at 10-18%',
    teaser: 'A foundational multi-decade study directly comparing seven countries found cardiovascular disease running roughly twice as common in Northern Europe and North America as in Mediterranean southern Europe and Japan.',
    summary: "The already-cited Mediterranean-diet research traces directly back to a foundational piece of international epidemiology: the Seven Countries Study, the first major research effort to directly compare cardiovascular disease rates across different countries and diets. Its 25-year follow-up data found cardiovascular disease prevalence running 2-10% in southern European (Mediterranean) countries, compared with 10-18% in northern European countries, a roughly two-to-fivefold difference, with Japan showing a similarly low rate to southern Europe. The documented explanation centers on diet: cohorts following a Mediterranean-style diet (high in olive oil, legumes, vegetables, and fiber, low in saturated fat) showed measurably lower cardiovascular risk and death rate, while cohorts eating a diet higher in saturated fat and lower in these protective foods showed the reverse. Current global burden data shows this picture has shifted since the original study: cardiovascular disease burden is now rising fastest in low- and middle-income countries as diets and lifestyles shift toward the same Western pattern already linked to higher risk in the original northern-Europe cohorts, meaning the historical 'low-risk' regions of this original study aren't a fixed, permanent category, but a moving target tied to what people are actually eating today.",
    citations: [
      { source: 'How the Seven Countries Study contributed to the definition and development of the Mediterranean diet concept: A 50-year journey, Nutrition, Metabolism and Cardiovascular Diseases', url: 'https://www.nmcd-journal.com/article/S0939-4753(14)00347-0/abstract' },
      { source: 'Ancel Keys, the Mediterranean Diet, and the Seven Countries Study: A Review, PMC12027923', url: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC12027923/' },
    ],
    overallTier: 'strong',
    relatedIds: ['cvd-overview', 'cvd-mediterranean-diet-predimed'],
  },
  {
    id: 'cvd-global-russia-post-soviet-crisis',
    category: 'cardiovascularDisease',
    title: "Russia's Record Cardiovascular Death Rate Went Beyond Diet",
    teaser: 'Documented cardiovascular mortality in Russia reached levels nearly four times higher than the US, a crisis conventional risk factors like diet and cholesterol could not fully explain.',
    summary: "The Seven Countries Study ties cardiovascular risk directly to diet, and Russia's documented mortality crisis shows that story isn't the whole picture. Data found premature cardiovascular death among Russian men reaching nearly 500 per 100,000, a level never before observed anywhere in the world, roughly twice as high as the peak the United States ever reached even in the 1960s, and almost four times the equivalent US rate. This tracked closely with the fall of the Soviet Union: cardiovascular mortality in Eastern Europe was low as recently as the early 1960s, rose steadily through the following decades, then spiked sharply after the severe economic and social disruption following 1990. Research finds a substantial share of this excess mortality can't be explained by the usual, cardiovascular risk factors (diet, cholesterol, blood pressure) alone, with separate research pointing toward psychosocial stress, alcohol, and non-ischemic cardiac damage as additional contributors specific to this crisis. This is an important complication to keep alongside this category's diet-focused Mediterranean research, cardiovascular risk is largely food-driven in most contexts, but a documented historical crisis shows that severe social and economic upheaval can independently drive cardiovascular mortality to levels diet alone doesn't explain.",
    chart: {
      title: 'Premature cardiovascular mortality, men (per 100,000)',
      unit: 'per 100,000',
      data: [
        { label: 'Russia (post-Soviet peak)', value: 500 },
        { label: 'United States (equivalent era)', value: 125 },
      ],
      sourceNote: 'The Epidemic of Cardiovascular Disease in Eastern Europe, New England Journal of Medicine',
    },
    citations: [
      { source: 'The Epidemic of Cardiovascular Disease in Eastern Europe, New England Journal of Medicine', url: 'https://www.nejm.org/doi/full/10.1056/NEJM199706263362614' },
      { source: "Why does Russia have such high cardiovascular mortality rates?, PMC7577103", url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577103/' },
    ],
    overallTier: 'strong',
    relatedIds: ['cvd-global-seven-countries-mediterranean'],
  },
  {
    id: 'horizon-cvd',
    category: 'cardiovascularDisease',
    title: 'This Category\'s Named Blind Spot, Lipoprotein(a), Finally Has Drugs Being Tested Against It',
    teaser: 'This category already names lipoprotein(a) as a largely genetic risk factor with no treatment, and two drugs now in late-stage trials cut it by up to 95%, with cardiovascular-outcome results expected as soon as 2026.',
    summary:
      "The lipoprotein(a) research names a gap directly: it's a largely genetic, roughly 20%-of-the-population cardiovascular risk factor most people are never even tested for, and until recently, no treatment existed to lower it the way statins lower LDL cholesterol. That's now changing. Pelacarsen, a drug that blocks the genetic instructions for making Lp(a) in the first place, lowered Lp(a) levels by roughly 80% in Phase 2 testing, and is now in a Phase 3 trial (HORIZON) enrolling 8,323 people with existing cardiovascular disease and high Lp(a), with outcome data expected as soon as the first half of 2026. A second, newer drug, olpasiran, showed even more striking Phase 2 results, cutting Lp(a) levels by more than 95%, and is now in its Phase 3 outcomes trial with 7,297 participants. Both drugs currently lower the LEVEL of Lp(a) in the blood, measured, and dramatic, but neither has yet proven in a completed outcomes trial that doing so actually reduces heart attacks and strokes, the final, still-pending question both of these late-stage trials exist specifically to answer.",
    citations: [
      { source: 'Emerging therapies targeting lipoprotein(a): the next frontier in cardiovascular risk reduction', url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12756449/' },
      { source: 'Ongoing Clinical Trials Targeting Lipoprotein(a), Family Heart Foundation', url: 'https://familyheart.org/lpa-clinical-trials' },
    ],
    overallTier: 'strong',
    relatedIds: ['cvd-lipoprotein-a-underrecognized'],
  },
  {
    id: 'horizon-cvd-colchicine',
    category: 'cardiovascularDisease',
    title: "A Cheap, Century-Old Gout Drug Just Became the First FDA-Approved Anti-Inflammatory Heart Drug",
    teaser: "The CANTOS trial first proved inflammation itself independently drives heart attacks. A low-dose, already-cheap drug just became the first medication ever approved specifically to act on that finding directly.",
    summary: "The CANTOS trial was the first proof that treating inflammation itself, independent of cholesterol, reduces cardiovascular events. Low-dose colchicine, an already well-known, inexpensive drug most commonly used for gout (covered in the Gout research), turned out to be the practical drug that finally translated that finding into an approved treatment. A large trial (LoDoCo2), randomizing 5,522 people with existing cardiovascular disease to 0.5mg colchicine daily or placebo, found a 31% reduction in major cardiovascular events, heart attack, stroke, and the need for an artery-opening procedure, over a median follow-up of 28.6 months. It received FDA approval in June 2023, becoming the first-ever anti-inflammatory drug specifically approved to reduce cardiovascular risk, distinct from every cholesterol-lowering drug. Colchicine's anti-inflammatory effect (measurably lowering CRP) is well established, but the field itself states plainly that the exact mechanism connecting that effect to fewer heart attacks isn't yet fully understood, working evidence ahead of a complete explanation for why it works.",
    citations: [
      { source: 'U.S. FDA Approves First Anti-Inflammatory Drug for Cardiovascular Disease', url: 'https://www.dicardiology.com/content/us-fda-approves-first-anti-inflammatory-drug-cardiovascular-disease' },
      { source: 'Potential Impact of Colchicine on Atherosclerotic Cardiovascular Disease in the United States, PMC11872516', url: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11872516/' },
    ],
    overallTier: 'strong',
    relatedIds: ['cvd-cantos-inflammation-hypothesis', 'horizon-cvd'],
  },
  {
    id: 'cvd-post-mi-depression-mortality',
    category: 'cardiovascularDisease',
    title: 'Depression After a Heart Attack Is Common, and Carries a Mortality Risk, One That Treatment Improves',
    teaser: 'Roughly two-thirds of heart attack patients report depressive symptoms, and a striking finding: untreated depression carries up to 90% higher one-year mortality than treated depression or no depression at all.',
    summary:
      'Research finds a high depression burden right after a heart attack: roughly 65 percent of acute myocardial infarction patients report depressive symptoms, with major depression present in 15 to 22 percent. Pooled data finds post-MI depression associated with a roughly doubled risk of all-cause mortality (odds ratio 2.25), and someone who is both depressed and already has cardiovascular disease carries a 3.5-fold higher death risk than someone with cardiovascular disease alone. The most actionable finding in this whole entry: patients with untreated depression showed a 70 to 90 percent higher one-year mortality risk after their heart attack than patients who were either not depressed or whose depression was actually treated, a direct, hopeful reason to treat post-MI depression seriously, not dismiss it as an understandable but ultimately separate reaction to a frightening diagnosis. Some methodologically strong studies have failed to find depression independently raising cardiac death risk after MI, and the relationship appears complex, possibly concentrated specifically in the period immediately following the event rather than a fixed, permanent risk factor.',
    citations: [
      { source: 'Depression Is a Risk Factor for Mortality After Myocardial Infarction: Fact or Artifact?, Journal of the American College of Cardiology', url: 'https://www.jacc.org/doi/10.1016/j.jacc.2007.01.075' },
      { source: 'Depression Treatment and 1-Year Mortality After Acute Myocardial Infarction, Circulation', url: 'https://www.ahajournals.org/doi/10.1161/circulationaha.116.025140' },
    ],
    overallTier: 'strong',
    relatedIds: ['mentalhealth-overview', 'mentalhealth-when-to-seek-help'],
  },
  {
    id: 'cvd-potassium-salt-substitute-real-trial',
    category: 'cardiovascularDisease',
    title: 'A 21,000-Person Trial Found a Simple Salt Swap Cut Stroke and Death Risk',
    teaser: "The Salt Substitute and Stroke Study replaced regular table salt with a potassium-enriched version in high-risk adults and found significant reductions in stroke, major cardiac events, and death.",
    summary:
      "The DASH/sodium research shows reducing sodium intake lowers blood pressure, and a large, cluster-randomized trial (SSaSS, published in the New England Journal of Medicine) tested a practical way to do it at scale: swapping regular salt (100 percent sodium chloride) for a salt substitute (75 percent sodium chloride, 25 percent potassium chloride) in 20,995 Chinese adults with a stroke history or older age plus uncontrolled hypertension. The results were significant across every major outcome tracked: reduced systolic blood pressure, and statistically significant reductions in stroke, major cardiovascular events, and total mortality, all from what amounts to changing which container of salt sits on the table. A follow-up analysis found the benefit specifically traced to both halves of the swap, less sodium and more potassium, each independently contributing to the blood-pressure reduction observed. This is one of the largest, most practical, most directly actionable cardiovascular prevention trials in recent years, evidence that a small, low-cost dietary substitution, not a new drug, produced a measured reduction in stroke and death in a high-risk population, though the same potassium increase this trial relied on is worth checking against any existing kidney disease or potassium-sensitive medication.",
    citations: [
      { source: 'Effect of Salt Substitution on Cardiovascular Events and Death, New England Journal of Medicine, PMID 34459569', url: 'https://www.nejm.org/doi/full/10.1056/NEJMoa2105675' },
      { source: 'The contribution of sodium reduction and potassium increase to the blood pressure lowering observed in the Salt Substitute and Stroke Study, PMC11001572', url: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11001572/' },
    ],
    overallTier: 'strong',
    relatedIds: ['cvd-dash-sodium', 'ckd-potassium-restriction-reconsidered'],
  },
  {
    id: 'cvd-statin-nocebo-muscle-pain',
    category: 'cardiovascularDisease',
    title: "Statin Muscle Pain Is a Patient Experience, but Blinded Trials Find It's Usually Not the Drug",
    teaser: "A large individual-participant meta-analysis found muscle symptoms occurred at the same rate on statins and placebo, when neither the patient nor the doctor knew which was which.",
    summary:
      "The statin evidence is strong on mortality and cardiovascular-event benefit, but muscle pain remains the single most common reason people stop taking one, and research finds something counterintuitive underneath it. A large individual-participant-data meta-analysis of double-blind, placebo-controlled trials found muscle symptoms occurred at essentially the same rate in the statin group and the placebo group, and calculated that only about 1 in 15 muscle-symptom reports among people actually taking a statin were caused by the drug itself. The direct explanation is the nocebo effect, the same phenomenon as a placebo effect but working in reverse, where expecting a side effect increases the odds of reporting one. Research confirms this directly: when patients don't know whether they're taking a statin or a placebo, muscle-symptom reports match; when they do know, statin-group reports rise. A separate finding backs this further: most patients previously labeled statin-intolerant in ordinary practice tolerate the same drug fine under blinded conditions. This doesn't mean statin-related muscle pain is never for a given individual, only that controlled evidence finds it's usually not the pharmacological cause most people assume, worth discussing directly with a doctor (including a blinded rechallenge) before abandoning a drug with this category's well-documented mortality benefit.",
    citations: [
      { source: 'Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials, PMC7613583', url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7613583/' },
      { source: 'The nocebo effect in the context of statin intolerance, PMID 27578103', url: 'https://pubmed.ncbi.nlm.nih.gov/27578103/' },
    ],
    overallTier: 'strong',
    relatedIds: ['cvd-statin-evidence'],
  },
  {
    id: 'cvd-cardiac-rehab-real-barriers-completion',
    category: 'cardiovascularDisease',
    title: "Why So Few People Actually Finish Cardiac Rehab, Once They're Even Referred",
    teaser: "The cardiac-rehab mortality benefit is strong, but research finds the gap between being eligible and actually completing the program is even wider than the enrollment numbers alone suggest.",
    summary:
      "The cardiac rehabilitation research shows a substantial mortality benefit sitting largely unused, and research digs further into exactly why. A study of 16,159 eligible patients found only 44.3 percent were even referred to cardiac rehabilitation in the first place, and of those, just 11.2 percent went on to actually complete it, a much steeper drop-off than the overall enrollment figures alone suggest. Identified barriers, drawn from qualitative and quantitative research together, include a lack of medical referral (31 percent), other concurrent medical problems (28 percent), the patient declining (11 percent), and simple geographic distance from the facility (9 percent). A separate study of heart failure patients specifically found 65 percent had never been enrolled at all. Research also identifies who's most at risk of not finishing once started: living alone, having diabetes, or having depression all independently predicted non-completion, while older age and COPD predicted never enrolling in the first place. Given the mortality benefit, the single most actionable finding here is that a lack of referral is the single largest identified barrier, meaning directly asking a cardiologist for a cardiac rehab referral, rather than waiting to be offered one, is a concrete step someone can take themselves.",
    citations: [
      { source: 'Cardiac Rehabilitation Completion Study: Barriers and Potential Solutions, PMID 36044761', url: 'https://pubmed.ncbi.nlm.nih.gov/36044761/' },
      { source: 'Increasing Cardiac Rehabilitation Participation From 20% to 70%: A Road Map From the Million Hearts Cardiac Rehabilitation Collaborative, PMC5292280', url: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC5292280/' },
    ],
    overallTier: 'strong',
    relatedIds: ['cvd-cardiac-rehabilitation-underused', 'mentalhealth-overview'],
  },
  {
    id: 'cvd-pad-supervised-exercise-real-data',
    category: 'cardiovascularDisease',
    title: "Supervised Exercise Outperforms a Home Walking Program for Peripheral Artery Disease",
    teaser: "The kidney-brain-PAD entry names PAD as a systemic manifestation of atherosclerosis, pooled trial data finds a structured, supervised walking program adding roughly 180 meters to maximum walking distance, more than unsupervised walking alone.",
    summary:
      "The vascular research already names peripheral artery disease (PAD) as a systemic form of the same atherosclerotic process behind heart attack and stroke, and pooled trial data gives a specific, evidence-backed treatment its direct weight. A meta-analysis of 25 studies (1,054 patients) with intermittent claudication (the classic PAD symptom, leg pain during walking that resolves with rest) found supervised treadmill exercise programs increased maximum walking distance by an average of 180 meters and pain-free walking distance by 125 meters. The worth-knowing distinction is between supervised and unsupervised exercise specifically: a larger systematic review and meta-analysis (27 studies, 2,074 patients) found supervised programs meaningfully outperforming a simple 'go walk more at home' recommendation, evidence that the structure itself, not just the activity, drives much of the benefit. A separate randomized trial found supervised exercise measurably improving cardiorespiratory fitness and reducing perioperative risk, directly relevant for anyone facing the vascular procedures. Supervised exercise therapy for PAD is formally recommended by the American Heart Association, and, in the US, a covered Medicare benefit, worth specifically requesting a referral for rather than assuming a general 'walk more' suggestion covers the same ground.",
    citations: [
      { source: 'Implementation of Supervised Exercise Therapy for Patients With Symptomatic Peripheral Artery Disease: A Science Advisory From the American Heart Association, PMID 31446770', url: 'https://pubmed.ncbi.nlm.nih.gov/31446770/' },
      { source: 'Endovascular Revascularization and Supervised Exercise for Peripheral Artery Disease and Intermittent Claudication: A Randomized Clinical Trial, JAMA', url: 'https://jamanetwork.com/journals/jama/fullarticle/2468892' },
    ],
    overallTier: 'strong',
    relatedIds: ['cvd-kidney-brain-pad-real-data', 'cvd-cardiac-rehabilitation-underused'],
  },
  {
    id: 'cvd-hfpef-sglt2-emperor-preserved',
    category: 'cardiovascularDisease',
    title: 'A Landmark Trial Found the First Effective Drug for the Heart-Failure Type That Had None',
    teaser: 'EMPEROR-Preserved, a 5,988-patient trial, found empagliflozin the first therapy ever to significantly reduce death and hospitalization specifically in heart failure with preserved ejection fraction.',
    summary:
      "The heart-failure ABCD staging names distinct stages of the disease, and heart failure with preserved ejection fraction (HFpEF, where the heart's pumping chamber squeezes normally but doesn't relax and fill properly) had lacked an effective drug treatment until recent trial data changed that. The EMPEROR-Preserved trial, a large (5,988 patients, mean age 75), randomized, placebo-controlled study, found empagliflozin (an SGLT2 inhibitor, the same drug class covered elsewhere in this app for its kidney and diabetes benefits) reduced the combined risk of cardiovascular death or heart-failure hospitalization by 21 percent, with only 31 patients needing treatment to prevent one event. Research directly names this the first therapy ever to significantly improve outcomes specifically in HFpEF, an important gap this trial closed, since HFpEF has historically proven much harder to treat effectively than the reduced-ejection-fraction type most heart-failure drugs were originally developed for. A broader systematic review of the SGLT2-inhibitor class in HFpEF found the benefit consistent across multiple trials, not a one-off result, with additional improvement in functional capacity and reduced hospitalizations. This is substantial, practice-changing evidence, and given SGLT2 inhibitors' benefit across diabetes, kidney disease, and now this specific heart-failure type, it's especially relevant for anyone managing HFpEF alongside any of those other conditions.",
    citations: [
      { source: 'The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial, PMC8604725', url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604725/' },
      { source: 'Empagliflozin in Heart Failure with a Preserved Ejection Fraction, New England Journal of Medicine', url: 'https://doi.org/10.1056/NEJMoa2107038' },
    ],
    overallTier: 'strong',
    relatedIds: ['cvd-heart-failure-abcd-staging', 'ckd-sglt2-inhibitors'],
  },
  {
    id: 'cvd-afib-catheter-ablation-real-trial',
    category: 'cardiovascularDisease',
    title: "For AFib With Heart Failure, a Trial Found Catheter Ablation Reduced Death and Hospitalization",
    teaser: "The atrial-fibrillation entry names anticoagulation as the established stroke-prevention treatment, a separate, direct treatment approach, catheter ablation, was found to improve survival specifically in patients who also have heart failure.",
    summary:
      "The atrial-fibrillation research names anticoagulation as the well-established treatment for the stroke risk AFib carries, and catheter ablation addresses a different question: whether directly treating the irregular heart rhythm itself, not just preventing its clotting consequences, improves outcomes. A randomized trial (published in the New England Journal of Medicine) specifically enrolled patients with both symptomatic AFib and heart failure (NYHA class II-IV, ejection fraction 35 percent or less) and compared catheter ablation against standard medical therapy including antiarrhythmic drugs. The result: catheter ablation was associated with a significant reduction in both mortality and heart-failure-related hospitalizations, alongside measured improvement in left ventricular ejection fraction itself, a more direct benefit than symptom control alone. Pooled safety data across multiple studies found the procedure's periprocedural complication rate at 2.9 percent, useful context for weighing the decision. This is meaningful evidence specifically for the AFib-plus-heart-failure combination, a distinct treatment path from anticoagulation alone, worth discussing directly with a cardiologist for anyone managing both conditions together, not a universal AFib recommendation for every patient regardless of whether heart failure is also present.",
    citations: [
      { source: 'Catheter Ablation for Atrial Fibrillation with Heart Failure, New England Journal of Medicine', url: 'https://www.nejm.org/doi/full/10.1056/NEJMoa1707855' },
      { source: 'Complications of catheter ablation of atrial fibrillation: a systematic review, PMID 24243785', url: 'https://pubmed.ncbi.nlm.nih.gov/24243785/' },
    ],
    overallTier: 'strong',
    relatedIds: ['cvd-atrial-fibrillation-anticoagulation', 'cvd-heart-failure-abcd-staging'],
  },
  {
    id: 'cvd-moderate-statin-ezetimibe-vs-high-intensity',
    category: 'cardiovascularDisease',
    title: 'A Trial Found a Gentler Combination Matched High-Dose Statin Alone',
    teaser: "The statin evidence establishes the drug class's mortality benefit, a direct comparison trial found an alternative path to the same LDL target that doesn't require pushing one drug to its highest, most side-effect-prone dose.",
    summary:
      "The statin research establishes the class-wide mortality and event-reduction benefit tied to how much LDL cholesterol actually comes down, not to any one specific drug or dose. A direct question follows from that: does the LDL reduction have to come from a high-intensity statin dose alone, or can a moderate dose combined with a second, different drug (ezetimibe, which blocks cholesterol absorption in the gut through a completely different mechanism) get there just as safely and effectively? The RACING trial, a randomized comparison in patients with established atherosclerotic cardiovascular disease, found moderate-intensity statin plus ezetimibe produced a three-year composite outcome (cardiovascular death, major cardiovascular events, or nonfatal stroke) that was statistically comparable to high-intensity statin monotherapy, with the result holding consistently regardless of sex. A separate, large nationwide cohort study of patients with acute coronary syndrome found the combination approach tracked with a numerically lower adverse-outcome rate than high-intensity monotherapy (12.1 percent versus 13.3 percent), and a pooled meta-analysis across 32 studies found the combination approach achieved lower LDL-C levels than monotherapy overall. This doesn't reduce the already-established value of statins themselves, it's useful evidence that reaching an LDL target doesn't require one single path, and a practical option worth discussing directly with a doctor for anyone who experiences muscle-related side effects at a higher statin dose (see the nocebo-effect research for how to tell a drug effect from an actual but non-pharmacological one first).",
    citations: [
      { source: 'Comparative outcomes of moderate-intensity statin with ezetimibe vs high-intensity statin therapy, ScienceDirect', url: 'https://www.sciencedirect.com/science/article/abs/pii/S193328742500409X' },
      { source: 'Comparative effectiveness of moderate-intensity statin with ezetimibe therapy versus high-intensity statin monotherapy, PMC10774297', url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10774297/' },
    ],
    overallTier: 'strong',
    relatedIds: ['cvd-statin-evidence', 'cvd-statin-nocebo-muscle-pain'],
  },
  {
    id: 'cvd-tavr-vs-surgery-low-risk-partner3',
    category: 'cardiovascularDisease',
    title: 'A Landmark Trial Found a Minimally Invasive Valve Procedure Now Matches Open-Heart Surgery, Even in Low-Risk Patients',
    teaser: "The atrial-fibrillation-ablation research names a minimally invasive alternative to lifelong medication, for a different heart problem, a narrowed aortic valve, a 5-year landmark trial found the same kind of catheter-based approach now matches traditional open-heart surgery, even in low-risk patients.",
    summary:
      "The research on catheter-based procedures shows a general shift toward less invasive treatment options, and transcatheter aortic-valve replacement (TAVR), a catheter-delivered valve replacement for aortic stenosis (a narrowed, hardened heart valve) done without opening the chest, is a major example. TAVR was originally approved only for patients too frail or high-risk for open-heart surgery, and the direct question was whether it could actually match surgery for healthier, LOWER-risk patients too. The PARTNER 3 trial, a landmark randomized trial, directly tested this in low-risk patients with severe, symptomatic aortic stenosis and found, at 5-year follow-up, no statistically significant difference between TAVR and surgery on the combined outcome of death, stroke, or rehospitalization (22.8 percent with TAVR versus 27.2 percent with surgery, a non-significant difference given the trial's confidence interval). A separate trial (Evolut Low Risk) confirmed the same pattern out to 6 years, finding no significant difference in all-cause mortality or disabling stroke between the two approaches, direct evidence this isn't a short-term finding that fades with longer follow-up. This durable, multi-year evidence is exactly why TAVR has moved from a last-resort option for frail patients to an evidence-backed alternative to open-heart surgery for aortic stenosis across a much broader range of patients, worth a direct conversation about which approach fits a specific case, rather than assuming open-heart surgery remains the only proven option.",
    citations: [
      { source: 'Transcatheter Aortic-Valve Replacement in Low-Risk Patients at Five Years, New England Journal of Medicine, PMID 37874020', url: 'https://pubmed.ncbi.nlm.nih.gov/37874020/' },
    ],
    overallTier: 'strong',
    relatedIds: ['cvd-afib-catheter-ablation-real-trial', 'cvd-elderly-atypical-mi-presentation'],
  },
  {
    id: 'cvd-tmao-gut-microbiome-real-data',
    category: 'cardiovascularDisease',
    title: 'A Gut-Bacteria-Produced Compound Independently Predicts Heart Attack Risk, Beyond Standard Risk Factors',
    teaser: "The lipid-panel and lipoprotein(a) research names standard risk markers, TMAO, a compound gut bacteria produce from dietary choline and carnitine, predicts cardiovascular events on its own, independent of every traditional risk factor already measured.",
    summary: "The lipid-panel and lipoprotein(a) research names standard cardiovascular risk markers, and TMAO (trimethylamine N-oxide), a gut-microbiome-produced metabolite, adds a different kind of risk signal, one that originates in the gut rather than the liver or blood vessels directly. TMAO is produced when gut bacteria metabolize dietary choline, L-carnitine, and lecithin (found in red meat, egg yolks, and certain other foods), and a direct study of acute coronary syndrome patients found elevated TMAO levels predicting substantial increases in cardiovascular risk: people in the highest TMAO quartile had a 6.3-fold higher odds of a major cardiac event within 30 days, and a 1.81-fold higher risk of death at 7 years, compared with the lowest quartile, even after adjusting for traditional risk factors. A separate, independent Swiss cohort of 1,683 patients confirmed the same pattern, finding a 1.57-fold higher 1-year cardiac-event risk in the highest TMAO group. Broader research finds TMAO's elevated levels also independently associated with heart failure, hypertension, and arrhythmia, not just heart attack risk alone, evidence of a wide cardiovascular reach for one gut-derived compound. This independent, gut-microbiome-driven risk pathway is a different lever from cholesterol or blood pressure, as ongoing research increasingly connects gut health (already a recurring theme across the broader research) to cardiovascular outcomes specifically, not just digestive or autoimmune ones.",
    citations: [
      { source: 'Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors, European Heart Journal', url: 'https://academic.oup.com/eurheartj/article/38/11/814/2889390' },
    ],
    overallTier: 'strong',
    relatedIds: ['cvd-lipoprotein-a-underrecognized', 'gut-scfa-treg', 'cvd-legumes-cruciferous-sex-specific-young-adults'],
  },
  {
    // 2026-08-19, direct request following a Gut Insiders podcast mention:
    // find the actual study behind "beans for men, broccoli for women,"
    // check whether male and female gut microbiomes are actually different,
    // and explain why young adults specifically should care. The primary
    // finding was independently confirmed verbatim via a direct fetch of the
    // Edith Cowan University repository's own abstract page for the paper
    // itself (the ScienceDirect journal page was not directly fetchable).
    // The sex-hormone-and-microbiome claim deliberately stays limited to the
    // one specific, directly-verified finding (the postmenopausal shift) from
    // a real peer-reviewed review, rather than more granular taxonomic claims
    // that turned up only in a single aggregated search summary and could not
    // be independently confirmed against a primary source, the same
    // discipline already used to catch and discard an inaccurate claim about
    // chickpeas and butyrate earlier in this same research pass.
    id: 'cvd-legumes-cruciferous-sex-specific-young-adults',
    category: 'cardiovascularDisease',
    title: 'Legumes for Men, Cruciferous Vegetables for Women? A Young-Adult Study Found a Sex-Specific Pattern, With a Wide Confidence Interval',
    teaser: "A Western Australian cohort tracked since before birth found legume intake tracking with lower cardiometabolic risk specifically in men at age 22, and cruciferous vegetable intake tracking with lower risk specifically in women. Neither food group was shown to do nothing for the other sex, only that this particular study lacked the statistical power to prove a matching effect there too.",
    summary:
      "The Raine Study is a Western Australian cohort followed since before birth, and this analysis drew on 638 of its participants at the 22-year follow-up (53% female, mean age 22.1), using a food-frequency questionnaire to sort vegetable groups (allium, cruciferous, green leafy, legumes, and yellow-orange-red) against an International Diabetes Federation cardiometabolic-risk classification. After adjusting for income, physical activity, smoking, education, other vegetable intake, total energy, and saturated fat, one added daily 75-gram serving of legumes (peas, green beans, baked beans, soybeans, and other beans) tracked with about 72% lower odds of cardiometabolic risk in men specifically (OR 0.278, 95% CI 0.088-0.883, p=0.030), while one added serving of cruciferous vegetables (cabbage, cauliflower, broccoli) tracked with about 85% lower odds of cardiometabolic risk in women specifically (OR 0.151, 95% CI 0.023-0.999, p=0.049). That second figure's confidence interval runs from 0.023 all the way to 0.999, essentially touching the point where an effect disappears entirely, an unusually wide range for a finding built on a fairly small subgroup. Green leafy vegetables showed an initial difference between low- and high-risk women too, but that association didn't survive the full statistical adjustment, while the cruciferous one did. None of this means legumes do nothing for women or cruciferous vegetables do nothing for men; a cross-sectional study splitting 638 people by sex has limited power to detect a matching effect in either smaller subgroup, and not reaching statistical significance there is a different claim from disproving a benefit. The study's researchers floated a hormone-linked explanation without treating it as settled: compounds in legumes may interact more strongly with testosterone, while compounds in cruciferous vegetables may interact more with estrogen and progesterone. That speculation lines up with a separate, already-established body of research: a review of the gut-microbiota-sex-hormone relationship found urinary estrogen levels tracking closely with gut microbiota richness and diversity in men and in postmenopausal women, but not in premenopausal women, and that after menopause, a woman's gut microbiota composition shifts to resemble a man's more closely than it resembles her pre-menopause profile, confirming sex hormones do shape the gut microbiome in a measurable way, even though this particular cardiometabolic study never tested microbiome composition directly. The age of this cohort is itself part of the point: the researchers wrote that risk factors typically associated with much older age are already appearing at this life stage, in a population still generally considered healthy, meaning the food pattern someone settles into by their early 20s is already measurably connected to cardiometabolic risk, not something to defer thinking about until later in life. Both food groups also respond directly to preparation, a point this app's research on cruciferous vegetables and on chickpeas covers: cooking reduces the raw compounds in crucifers that can interfere with thyroid function while the cancer-related benefits largely survive, and cooking legumes and then cooling them before eating measurably raises their resistant-starch content, the same fraction gut bacteria ferment into butyrate.",
    citations: [
      { source: 'Higher legume and cruciferous vegetable intakes are associated with lower cardiometabolic risk in young adults: a cross-sectional study, McNamara N, Blekkenhorst LC, Mori TA, Beilin LJ, O’Sullivan TA, Nutrition, Metabolism and Cardiovascular Diseases, 2026', url: 'https://ro.ecu.edu.au/ecuworks2022-2026/8106/' },
      { source: 'Beans for blokes, broccoli for women: Which veggies protect young hearts?, Edith Cowan University press release via EurekAlert, 2026', url: 'https://www.eurekalert.org/news-releases/1136157' },
      { source: 'Interaction between gut microbiota and sex hormones and their relation to sexual dimorphism in metabolic diseases, Santos-Marcos JA et al., Biology of Sex Differences, 2023, PMC9903633', url: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC9903633/' },
    ],
    overallTier: 'moderate',
    relatedIds: ['gut-scfa-treg', 'produce-cruciferous', 'produce-chickpeas', 'problem-raw-cruciferous', 'cvd-tmao-gut-microbiome-real-data'],
  },
  {
    id: 'cvd-myocardial-ischemia-neurogenesis-impairment',
    category: 'cardiovascularDisease',
    title: 'A Heart Attack Itself Measurably Suppresses New-Neuron Growth in the Brain, Not Just Blood Flow to It',
    teaser: "The kidney-brain-PAD research names chronic vascular disease reaching the brain, a separate study found an actual heart attack event itself directly suppresses hippocampal neurogenesis, lasting at least two months afterward, through an inflammatory pathway rather than a blood-flow one alone.",
    summary:
      "The research establishes chronic vascular disease reaching the brain over time; a more specific and more acute mechanism deserves direct coverage. A controlled study found that a heart attack itself (myocardial ischemia/reperfusion) directly and measurably reduces new-neuron production in the hippocampus, the effect showed up within 72 hours and remained significantly reduced a full two months later, alongside measurable impairment on both object-location and fear-conditioning memory tasks. The proposed mechanism is distinct from simple reduced blood flow: researchers found documented activation of the brain's immune cells (microglia and astrocytes) in the hippocampus within days of the cardiac event, and this inflammatory response, not cell death from oxygen deprivation, correlated with the drop in new-neuron production, evidence that a heart attack sets off a measurable inflammatory signal that reaches the brain and suppresses this specific process directly. This is animal research, not yet confirmed in humans, but it offers a concrete, mechanistic explanation for something already commonly observed clinically, memory and cognitive complaints following a cardiac event, beyond what reduced blood flow to the brain alone would explain.",
    citations: [
      { source: 'Myocardial Ischemia/Reperfusion impairs neurogenesis and hippocampal-dependent learning and memory, Brain, Behavior, and Immunity, Evonuk et al. 2016, PMC5511033', url: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC5511033/' },
    ],
    overallTier: 'moderate',
    relatedIds: ['cvd-kidney-brain-pad-real-data', 'neurogenesis-tying-together'],
  },
  {
    id: 'cvd-fermented-drinks',
    category: 'cardiovascularDisease',
    title: 'Fermented Drinks and Foods for Cardiovascular Disease',
    teaser: 'Beet Kvass and the Wild-Fermented Hibiscus Tonic both carry strong human trial evidence for lowering blood pressure specifically, the two best-matched claims in this app\'s whole fermentation collection.',
    summary: 'Beet Kvass\'s dietary nitrate content has systematic-review-level human trial evidence for measurably lowering blood pressure, and the Wild-Fermented Hibiscus, Ginger & Turmeric Tonic draws on hibiscus\'s separately documented, meta-analysis-level blood-pressure-lowering effect, two of the more solidly evidenced individual claims across this whole collection. Pu-erh-Style Fermented Tea and the Wild-Fermented Red Grape Tonic add cholesterol- and resveratrol-related interest on top, though the red grape angle stays an early, mostly animal-study finding. The caution: Ayran and Sobia both carry deliberate salt or a naturally sodium-bearing base, worth checking against a sodium-restricted heart diet, and several drinks in this collection (Doburoku, Makgeolli, Coconut Palm Wine-Style) carry alcohol content, worth discussing with your care team if you\'re on a blood thinner or have an arrhythmia history.',
    citations: [
      { source: 'Dietary Nitrate from Beetroot Juice for Hypertension: A Systematic Review, PubMed', url: 'https://pubmed.ncbi.nlm.nih.gov/30400267/' },
      { source: 'Systematic review and meta-analysis of the effects of Hibiscus sabdariffa on blood pressure and cardiometabolic markers, Nutrition Reviews', url: 'https://pubmed.ncbi.nlm.nih.gov/34927694/' },
    ],
    overallTier: 'moderate',
    relatedIds: [
      'recipe-ferment-beet-kvass',
      'recipe-ferment-tonic-hibiscus-ginger-turmeric',
      'recipe-ferment-puerh-style-tea',
      'lifestyle-alcohol-advisory',
    ],
  },
  // 2026-08-21, added after fact-checking NOVA's "The Truth About Fat"
  // (2020) documentary against the peer-reviewed literature, direct
  // request. The documentary itself is not treated as a citable source;
  // this traces to the primary study, independently verified via
  // WebSearch.
  {
    id: 'cvd-hypoadiponectinemia-independent-risk',
    category: 'cardiovascularDisease',
    title: 'Low Adiponectin Is an Independent Risk Factor for Coronary Artery Disease',
    teaser: 'Men with low adiponectin had double the rate of coronary artery disease in a landmark study, a risk factor that showed up independently of the standard risk factors already tracked.',
    summary: "Adiponectin, the fat-derived hormone covered in the Health Literacy hormones research, is directly cardioprotective: it improves insulin sensitivity and has documented anti-atherosclerotic and anti-inflammatory effects on blood vessels. A landmark study found that men with low adiponectin (below 4.0 micrograms per milliliter) had roughly double the rate of coronary artery disease compared to men with higher levels, and this held up as an independent risk factor even after accounting for the standard risk factors (blood pressure, cholesterol, smoking, diabetes). Later studies extended this to acute coronary events and stroke risk as well. This is a measurable hormonal thread running underneath cardiovascular risk, worth reading alongside the existing lipid-panel and inflammation research rather than as a separate, unrelated finding.",
    citations: [
      { source: 'Kumada M et al. 2003, Arteriosclerosis, Thrombosis, and Vascular Biology: Association of hypoadiponectinemia with coronary artery disease in men (PMID 12524229)', url: 'https://pubmed.ncbi.nlm.nih.gov/12524229/' },
    ],
    overallTier: 'strong',
    relatedIds: ['cvd-overview', 'cvd-lipid-panel-self-advocacy', 'adiponectin-overview', 'bodyfat-hadza-cardiovascular-health'],
  },
  // 2026-08-23, added after fact-checking the "How Not to Die" documentary
  // (2025) against the peer-reviewed literature, direct request. The
  // documentary itself is not treated as a citable source; this traces to
  // the primary trial data, independently verified via WebSearch. The full
  // trial descriptions live in plantBasedNutrition.ts (Basic Health); this
  // entry is the condition-specific application for someone who already
  // has diagnosed coronary artery disease.
  {
    id: 'cvd-plant-based-diet-existing-disease',
    category: 'cardiovascularDisease',
    title: 'For Someone Already Diagnosed, Two Trials Tested Whether a Plant-Based Diet Could Reverse It, Not Just Slow It',
    teaser: 'Most of this category\'s dietary evidence is about preventing cardiovascular disease. Two separate bodies of research specifically tested people who already had it.',
    summary:
      "Everything else in this category's dietary research (the Mediterranean-diet trial, DASH) is built around preventing cardiovascular disease or lowering risk in people who don't yet have a diagnosis. A different, smaller body of research specifically tested people who already had angiographically-confirmed coronary artery disease, asking whether intensive dietary change could reverse it, not just slow its progression. A randomized trial (the Lifestyle Heart Trial) found measured coronary regression in the intervention group against progression in the control group over one year, and a long-term, though uncontrolled, case series found disease arrest and partial reversal sustained over more than a decade in a group of severely-diseased patients nothing else had worked for. Both are covered in full, including their design strengths and limitations, in the Health Literacy research on plant-based nutrition and heart disease. This is a separate question from general prevention, worth raising with a cardiologist specifically in the context of existing, diagnosed disease, not a substitute for the statin and blood-pressure evidence covered in this same category.",
    citations: [
      { source: 'Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial, Ornish D et al., The Lancet, 1990, PMID 1973470', url: 'https://pubmed.ncbi.nlm.nih.gov/1973470/' },
    ],
    overallTier: 'moderate',
    relatedIds: ['pbn-ornish-lifestyle-heart-trial', 'pbn-esselstyn-cohort-longterm', 'cvd-mediterranean-diet-predimed', 'cvd-statin-evidence'],
  },
  {
    id: 'cvd-late-eating-nutrinet-sante',
    category: 'cardiovascularDisease',
    title: 'When You Eat Your First and Last Meal Tracks with Cardiovascular Risk, a Large Cohort Finds',
    teaser: 'A first meal after 9am or a last meal after 9pm both tracked with higher cardiovascular disease risk in over 100,000 people followed for more than a decade.',
    summary: "The NutriNet-Santé cohort followed over 100,000 people from 2009 to 2022, tracking both when meals happened and cardiovascular outcomes. A later first meal (after 9am, versus before 8am) and a later last meal (after 9pm, versus before 8pm) both tracked with higher cardiovascular disease risk, an effect especially pronounced among women. People eating dinner after 9pm specifically carried a 28% higher risk of stroke compared to those finishing dinner before 8pm, and a longer overnight fasting window tracked with lower stroke risk on its own. This is a large, long-running cohort, not a small pilot, but it's observational: it shows a measurable association between meal timing and cardiovascular outcomes, not proof that timing alone, independent of everything else a person eats and does, drives that risk. Read alongside this app's other cardiovascular findings (the Mediterranean diet, statin evidence) as one more checkable lever, not a replacement for any of them.",
    citations: [
      { source: 'Dietary circadian rhythms and cardiovascular disease risk in the prospective NutriNet-Santé cohort, Nature Communications', url: 'https://pubmed.ncbi.nlm.nih.gov/38097547/' },
    ],
    overallTier: 'moderate',
    relatedIds: ['chrono-late-eating-cardiovascular-risk', 'chrono-shift-work-metabolic-cardiovascular-risk', 'cvd-mediterranean-diet-predimed'],
  },

  // Complementary & Manual Therapies, added 2026-09-04, second pass of the
  // hands-on batch covering the remaining 13 conditions. Cardiovascular
  // disease gets two entries because it holds both halves of the story at
  // once: a well-designed trial where acupuncture helped a symptom, and
  // the clearest failed-replication case in this whole field.
  {
    id: 'complementary-cvd-acupuncture-angina',
    category: 'cardiovascularDisease',
    title: 'Acupuncture for Angina: Fewer Episodes, No Change in the Underlying Ischemia',
    teaser:
      'A four-armed trial found acupuncture on disease-affected points reduced angina frequency. Earlier pooled evidence found no change in ECG ischemia or nitroglycerin use.',
    summary:
      "Chronic stable angina is chest pain from a heart muscle not getting enough blood, and it is a good test case because it can be measured two ways: how often the pain happens, and whether the underlying blood supply problem changes. A 20-week randomized trial across five centers in China assigned 404 participants to one of four arms, which is unusually careful: acupuncture on points belonging to the meridian said to correspond to the heart, acupuncture on points on a non-affected meridian, sham acupuncture, and a wait list with no acupuncture at all. The disease-affected group had a significant reduction in how often angina struck and how severe it was, along with lower anxiety and depression scores and better physical functioning. Published in JAMA Internal Medicine in 2019. The qualification is the second measurement. Systematic reviews pooling the earlier angina trials found symptom relief without a reduction in ischemia on electrocardiography and without a drop in how much nitroglycerin people needed. Those two findings together describe something specific: an intervention that changed how much the chest pain intruded on daily life without evidence that it changed the blood supply causing it. For someone with angina that is still limiting despite treatment, that is a reasonable thing to want. It is not a reason to defer the treatments that address the artery itself, and chest pain that is new, worsening, or happening at rest is an emergency rather than something to book a session for.",
    citations: [
      {
        source:
          'Zhao L, Li D, Zheng H, et al. 2019: Acupuncture as Adjunctive Therapy for Chronic Stable Angina: A Randomized Clinical Trial (JAMA Intern Med 179(10):1388-1397)',
        url: 'https://pubmed.ncbi.nlm.nih.gov/31355870/',
      },
    ],
    overallTier: 'moderate',
    relatedIds: [
      'complementary-cvd-blood-pressure-replication',
      'handson-acupuncture-chronic-pain',
      'handson-safety-and-what-to-ask',
    ],
  },
  {
    id: 'complementary-cvd-blood-pressure-replication',
    category: 'cardiovascularDisease',
    title: 'The Blood Pressure Study That Chiropractors Themselves Could Not Reproduce',
    teaser:
      'A 2007 trial reported a 17-point drop in systolic pressure from one neck adjustment. A 2016 replication run at a chiropractic college found nothing.',
    summary:
      "This is the clearest example in this whole area of why one striking result is not an answer, and the original study is still quoted in clinics today. In 2007 the Journal of Human Hypertension published a double-blind, placebo-controlled pilot in 50 people with stage 1 hypertension, comparing a specific upper-neck chiropractic procedure against a sham. At eight weeks the treatment group's systolic pressure had fallen about 17 mmHg against about 3 mmHg for placebo, and diastolic about 10 against 2. A drop that size is larger than most single blood pressure drugs achieve, and the result was reported widely. In 2016 a follow-up ran at the Palmer Center for Chiropractic Research, funded through the National Center for Complementary and Alternative Medicine, in 51 people with prehypertension or stage 1 hypertension: six weeks of upper cervical manipulation twice weekly against a sham procedure. It did not lower systolic or diastolic pressure. The authors concluded the results did not support a larger trial. Two things make this instructive. The replication was run by chiropractic researchers at a chiropractic institution, so it cannot be waved away as hostile. And the first study was a pilot, which is what pilots are for: a promising number that has to survive being tested again, and this one did not. High blood pressure is treatable, damages arteries and kidneys silently for years, and is not a reasonable thing to manage with an adjustment.",
    citations: [
      {
        source:
          'Bakris G, Dickholtz M Sr, Meyer PM, et al. 2007: Atlas vertebra realignment and achievement of arterial pressure goal in hypertensive patients: a pilot study (J Hum Hypertens 21(5):347-352)',
        url: 'https://pubmed.ncbi.nlm.nih.gov/17252032/',
      },
      {
        source:
          'Goertz CM, Salsbury SA, Long CR, et al. 2016: Effect of Spinal Manipulation of Upper Cervical Vertebrae on Blood Pressure: Results of a Pilot Sham-Controlled Trial (J Manipulative Physiol Ther 39(5):369-380)',
        url: 'https://pubmed.ncbi.nlm.nih.gov/27157678/',
      },
    ],
    overallTier: 'moderate',
    relatedIds: [
      'complementary-cvd-acupuncture-angina',
      'handson-chiropractic-organ-claims',
      'handson-chiropractic-back-pain-evidence',
      'handson-safety-and-what-to-ask',
    ],
  },
  // Protein source and cardiovascular mortality, added 2026-09-23
  // alongside the type 2 diabetes and Health Literacy entries from the
  // same 2026 Cell Metabolism paper. Song 2016's finding that the signal
  // disappeared in people with no unhealthy lifestyle factor is the part
  // that keeps this entry honest, and it is kept in the summary rather
  // than buried in a caveat line.
  {
    id: 'cvd-protein-source-diet-mortality',
    category: 'cardiovascularDisease',
    title: 'Where Diet Protein Comes From Tracked With Heart Deaths More Closely Than How Much of It There Was',
    teaser:
      'Across cohorts totalling well over a million people, plant protein tracked with fewer cardiovascular deaths and animal protein with more. In one of them the association vanished entirely among people with no unhealthy lifestyle habits.',
    summary:
      "Three large analyses point the same direction. A 2020 BMJ meta-analysis pooled 32 cohorts covering 715,128 people and 113,039 deaths: plant protein carried a relative risk of 0.92 for death from any cause (95% CI 0.87 to 0.97) and 0.88 for cardiovascular death (CI 0.80 to 0.96), and an extra 3% of daily calories from plant protein tracked with 5% lower all-cause mortality. A 2016 JAMA Internal Medicine analysis of 131,342 people found animal protein was not associated with death from any cause (hazard ratio 1.02 per 10% of calories) but was associated with cardiovascular death (1.08, CI 1.01 to 1.16), while plant protein tracked with 0.90 all-cause and 0.88 cardiovascular mortality per 3% of calories. Swapping 3% of calories from processed red meat to plant protein carried a hazard ratio of 0.66. A 2020 NIH-AARP analysis of 416,104 people and 77,614 deaths found replacing 3% of calories from animal protein with plant protein tracked with 10% lower overall mortality and 11 to 12% lower cardiovascular mortality, with the largest shifts coming from eggs (24% in men, 21% in women) and red meat (13% and 15%). Two things stop this from being a causal claim. The JAMA analysis found the associations were confined to people carrying at least one unhealthy lifestyle factor, such as smoking, heavy drinking, excess weight or inactivity, and were not evident among people carrying none, which is what confounding tends to look like. And the only controlled feeding trial in this area ran four weeks in 20 healthy adults; restricting sulfur-containing amino acids there did lower total cholesterol and LDL alongside body weight, but 20 people over four weeks cannot tell anybody what happens to a heart over a decade.",
    citations: [
      { source: 'Song M et al. 2016: Association of Animal and Plant Protein Intake With All-Cause and Cause-Specific Mortality, JAMA Intern Med 176(10):1453-63, PMID 27479196', url: 'https://pubmed.ncbi.nlm.nih.gov/27479196/' },
      { source: 'Naghshi S et al. 2020: Dietary intake of total, animal, and plant proteins and risk of all cause, cardiovascular, and cancer mortality, BMJ 370:m2412, PMID 32699048', url: 'https://pubmed.ncbi.nlm.nih.gov/32699048/' },
      { source: 'Huang J et al. 2020: Association Between Plant and Animal Protein Intake and Overall and Cause-Specific Mortality, JAMA Intern Med 180(9):1173-84, PMID 32658243', url: 'https://pubmed.ncbi.nlm.nih.gov/32658243/' },
      { source: 'Richie JP et al. 2023: Dietary Methionine and Total Sulfur Amino Acid Restriction in Healthy Adults, J Nutr Health Aging 27(2):111-123, PMID 36806866', url: 'https://pubmed.ncbi.nlm.nih.gov/36806866/' },
    ],
    overallTier: 'moderate',
    relatedIds: [
      'cvd-mediterranean-diet-predimed',
      'cvd-plant-based-diet-existing-disease',
      'protein-animal-vs-plant-protein-mortality',
      'protein-sulfur-amino-acid-restriction-trial',
    ],
  },
];
